Oct 15 2026 09:11 PM EST
Humana Shares Jump After CMS Star Ratings Upgrade and BlackRock Joint Venture Announcement
Humana Inc. (NYSE:HUM) rallied more than 10% over the past five days, driven by a CMS release that lifted its 2027 Medicare Advantage Star Ratings and a strategic joint venture with BlackRock to expand its CenterWell senior‑care clinic network. The moves prompted a wave of analyst upgrades and reinforced investor confidence in the company’s adjusted earnings outlook.
CMS announced on Oct 8 that 95% of Humana’s Medicare Advantage members are now in plans rated four stars or higher, up from 20% a year earlier. The upgrade triggered a 16.5% intraday spike and contributed to a broader 12.24% gain attributed to upbeat MA growth sentiment. The same week, the company disclosed a $2.8 billion joint venture with BlackRock‑managed HPS Investment Partners to operate roughly 150 CenterWell clinics, a deal that lifted the stock another 2% and spurred analyst upgrades from Baird, Mizuho and others.
CMS Star Ratings Upgrade Fuels Near‑Term Upside
The 2027 Star Ratings placed 95% of Humana’s members in four‑star or better plans, with eleven additional contracts reaching four‑star status. Management indicated that the ratings could unlock roughly $4.8 billion in quality‑bonus payments for the 2028 bonus year, a catalyst that analysts cite as a primary driver of the recent price rally.
Joint Venture with BlackRock Expands Integrated‑Care Platform
On Oct 13, Humana announced a new JV with BlackRock (via HPS Investment Partners) to manage about 150 CenterWell senior primary‑care clinics. The transaction, valued at approximately $2.8 billion, replaces WCAS as the equity partner and is expected to reduce balance‑sheet liabilities while providing growth capital for clinic expansion. The announcement reinforced the company’s integrated‑care strategy and was reflected in a 2% share‑price rise.
Financial Performance and Guidance
Q2 2026 reported adjusted EPS of $7.61, a modest increase over the prior year, and YTD adjusted EPS of $17.91. Revenue grew to $40.9 billion, up 23% YoY. The company affirmed its FY 2026 adjusted EPS guidance at “at least $9.00,” while GAAP EPS guidance was revised downward to “at least $6.52” due to a Star‑ratings headwind for the bonus year.
Analyst Action Reinforces Sentiment
Following the Star Ratings release, Barclays upgraded Humana to Overweight with a price target of $515, and Cantor Fitzgerald raised its target to $460. Baird lifted its target to $596, while Mizuho increased its target to $495. The consensus 26‑analyst price target now sits at $425, up roughly 10% from the prior close.
Macro and Sector Context
An aging U.S. population continues to drive Medicare Advantage enrollment, supporting Humana’s projected 25% membership growth for FY 2026. Inflation‑related cost pressures remain a sector‑wide risk, as does the Medicare price‑negotiation authority under the Inflation Reduction Act. Nevertheless, broader economic tailwinds, including a stabilising labor market and continued U.S. manufacturing recovery, provide a supportive backdrop for health‑care spending.
Risks and Uncertainties
Key risks include potential changes to Medicare payment methodologies that could affect Star‑rating bonus payments, execution risk around the BlackRock CenterWell joint venture, and the ongoing GAAP EPS headwind from the 2026 Star Ratings adjustment. A fiduciary‑duty investigation announced on Sep 28 may also weigh on governance perception, though no financial impact has been disclosed. Investors should monitor the upcoming Q3 2026 earnings release (Nov 6) for any revisions to benefit‑ratio guidance and to gauge the durability of the Star Ratings advantage.